Want to see IRMD full AI Analyst Report?
IRMD Stock Chart & Stats
$76.42
$0.29(0.51%)
At close: 4:00 PM EST
$76.42
$0.29(0.51%)
Day’s Range― - ―
52-Week Range$55.11 - $107.90
Previous CloseN/A
Volume15.52K
Average Volume (3M)142.56K
Market Cap
$1.24B
Enterprise Value$1.11B
Total Cash (Recent Filing)$56.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)52.5
Beta0.63
Next Earnings
Jul 30, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield1.22%
Share Statistics
EPS (TTM)1.86
Shares Outstanding12,783,035
10 Day Avg. Volume119,257
30 Day Avg. Volume142,563
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue12.84
Enterprise Value/Gross Profit16.71
Enterprise Value/Ebitda34.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.08
Revenue Forecast (FY)$91.75M
Bulls Say, Bears Say
Bulls Say
High And Expanding MarginsSustained high gross margins (~76–77%) and an expanding EBIT margin (~34% TTM) indicate durable product-level economics and pricing power in MRI-compatible devices. Strong margins support reinvestment, funding for R&D, and cash returns while cushioning profitability through modest top-line variability.
Exceptionally Conservative Balance SheetAn effectively debt-free balance sheet with consistently strong ROE (~22–24%) gives long-term financial flexibility. Low leverage reduces default and refinancing risk, enables dividend payments and strategic investments, and provides capacity to fund manufacturing scale-up or targeted M&A without stressing cash flow.
Attractive 3870 Launch And Replacement RunwayEarly 3870 demand showing ~20% ASP lift and a quad-system mix raises per-order revenue and installed-channel economics. Coupled with a large domestic replacement pool (multiple thousands of legacy channels), this creates a durable revenue runway where capital sales drive recurring disposables, service, and monitoring revenue.
Bears Say
Manufacturing Ramp And Execution RiskA deliberately constrained 3870 shipment plan (130–135 units in Q2) highlights operational scaling risk. If supply chain stabilization or production know-how lags, revenue recognition and margin improvement tied to the new product could be delayed, risking longer conversion of demand into durable revenue.
Geographic ConcentrationWith ~82% of revenue generated domestically, the company is exposed to U.S. hospital capital cycles, reimbursement shifts, and regulatory changes. Limited international diversification increases sensitivity to single-market headwinds and may slow the company’s ability to smooth growth across business cycles.
Volatile Cash-flow Conversion HistoricallyWhile recent operating cash flow and free cash flow strengthened, historical uneven conversion (notably 2023) signals working-capital or timing volatility. Such swings can constrain funding for inventory build, ramping production, or sustaining dividends during periods when capital is needed to scale the business.
Iradimed News
IRMD FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was $55.11 and its highest was $107.90 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is $1.24B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Jul 30, 2026 which is in 16 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on May 01, 2026. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.445 by $0.045.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Overvalued.
Does Iradimed Corp pay dividends?
Iradimed Corp pays a Monthly dividend of $0.2 which represents an annual dividend yield of 1.22%. See more information on Iradimed Corp dividends here
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.44.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,783,035 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of $0.49 in its last earnings report, beating expectations of $0.445. Following the earnings report the stock price went up 4.447%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in IRMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
IRMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 11.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $285.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.72%
12-Months-Change
Fundamentals
Return on Equity
24.48%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Technical Analysis
Ownership Overview
34.87% Insiders
12.95% Mutual Funds
0.07% Other Institutional Investors
42.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---